Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

NMU-25 Inhibitors

Chemical inhibitors of NMU-25 employ various mechanisms to obstruct the protein's function. BIBN 4096 BS, PD 168368, SB-222200, SB-674042, SB-612111, T-2328, JNJ-5207787, and JNJ-17203212 are chemicals that directly target the neuromedin U receptor, which is the primary receptor through which NMU-25 exerts its effects. BIBN 4096 BS can inhibit NMU-25 by blocking the receptor interactions that NMU-25 relies on to initiate signaling. PD 168368 functions similarly, antagonizing the neuromedin U receptor to prevent NMU-25 from triggering its typical biological responses. SB-222200 and SB-674042 act as antagonists to this receptor, thereby blocking the downstream signaling events NMU-25 would usually activate. SB-612111 prevents NMU-25 from binding to its receptor, thwarting the subsequent signaling cascade. T-2328 also blocks the receptor targeted by NMU-25, preventing the protein from instigating its signaling pathway. JNJ-5207787 and JNJ-17203212 inhibit NMU-25 by binding with high affinity to its receptor, thus directly impeding NMU-25's receptor-mediated action.

On the other hand, Ononetin, Lestaurtinib, Erlotinib, and Sorafenib work by inhibiting downstream or parallel pathways to the NMU-25 signaling process. Ononetin interacts with kinase pathways that are activated following NMU-25 receptor interaction, thereby indirectly inhibiting the protein's effects. Lestaurtinib targets intracellular signaling mechanisms such as the JAK/STAT pathway, which NMU-25 may utilize for its biological activities, leading to an inhibition of NMU-25's function. Erlotinib inhibits NMU-25 by obstructing the epidermal growth factor receptor (EGFR) pathway, which, when inhibited, can reduce the functional activity of NMU-25. Lastly, Sorafenib blocks the RAF/MEK/ERK pathway, which is a critical signaling route that NMU-25 may influence, thus obstructing NMU-25's activities. Each of these inhibitors disrupts the signaling pathways in a manner that results in the functional inhibition of NMU-25, preventing it from carrying out its role in cellular processes.

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

JNJ 17203212

821768-06-3sc-204024
sc-204024A
10 mg
50 mg
$185.00
$781.00
(0)

JNJ-17203212 can inhibit NMU-25 by binding to its receptor with high affinity, thereby inhibiting NMU-25 induced receptor activation and signaling.

Lestaurtinib

111358-88-4sc-218657
sc-218657A
sc-218657B
1 mg
5 mg
10 mg
$275.00
$326.00
$612.00
3
(1)

Lestaurtinib can inhibit NMU-25 by targeting the intracellular signaling pathways such as JAK/STAT, which are involved in the signaling cascades of NMU-25, leading to inhibition of NMU-25's biological activities.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

Erlotinib can inhibit NMU-25 indirectly by inhibiting the epidermal growth factor receptor (EGFR) pathway which can have downstream effects on the signaling pathways NMU-25 is involved in, leading to its functional inhibition.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Sorafenib can inhibit NMU-25 by blocking the RAF/MEK/ERK pathway, which may be downstream or in parallel to NMU-25 signaling, thus inhibiting the functional activity of NMU-25.